Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib Durvalumab + Tremelimumab With First-Line Chemotherapy in Advanced Solid Tumors (Japan)
jRCT2080223710Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of durvalumab and tremelimumab in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC) and 7 more (7 cohorts), sponsored by AstraZeneca. Started Nov 2017; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)head and neck squamous cell carcinoma (HNSCC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on jRCT2080223710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223710.